BioMarin Pharmaceutical Inc. experienced a significant price increase of 13.00%, reaching a 20-day high amid positive market conditions, with the Nasdaq-100 up 0.81% and the S&P 500 up 0.22%.
This surge is attributed to BioMarin's announcement of a $4.8 billion acquisition of Amicus Therapeutics, which is expected to enhance its portfolio in rare disease treatments. The deal, valued at $14.50 per share, is anticipated to accelerate revenue growth and significantly impact BioMarin's earnings per share within the first year after closing, with substantial benefits expected starting in 2027.
The acquisition not only strengthens BioMarin's market position but also adds two high-growth therapies, Galafold and Pombiliti + Opfolda, which are projected to drive long-term revenue growth through 2030 and beyond.
Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.35 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.35 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
5 Hold
0 Sell
Moderate Buy
Current: 56.990
Low
60.00
Averages
87.35
High
120.00
Current: 56.990
Low
60.00
Averages
87.35
High
120.00
Barclays
Overweight
initiated
$80
2026-01-27
New
Reason
Barclays
Price Target
$80
AI Analysis
2026-01-27
New
initiated
Overweight
Reason
Barclays assumed coverage of BioMarin with an Overweight rating and $80 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Canaccord
Hold
to
Buy
upgrade
$84 -> $98
2026-01-20
Reason
Canaccord
Price Target
$84 -> $98
2026-01-20
upgrade
Hold
to
Buy
Reason
Canaccord upgraded BioMarin (BMRN) to Buy from Hold with a price target of $98, up from $84. The firm believes the pending acquisition of Amicus (FOLD) will be the catalyst to break BioMarin shares out of the recent trading range. As the deal closes, positive commercial and pipeline updates "could more meaningfully and durably shift sentiment" and help close BioMarin 's "valuation gap," the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMRN
Unlock Now
Leerink
Joseph Schwartz
Outperform
to
Market Perform
downgrade
$17
2025-12-29
Reason
Leerink
Joseph Schwartz
Price Target
$17
2025-12-29
downgrade
Outperform
to
Market Perform
Reason
Leerink analyst Joseph Schwartz downgraded Amicus (FOLD) to Market Perform from Outperform with a price target of $14.50, down from $17, following the recently announced acquisition by BioMarin (BMRN). The firm views BioMarin is a good strategic fit and thinks it is unlikely that another bid will emerge.
Truist
Joon Lee
Buy
maintain
$80 -> $100
2025-12-23
Reason
Truist
Joon Lee
Price Target
$80 -> $100
2025-12-23
maintain
Buy
Reason
Truist analyst Joon Lee raised the firm's price target on BioMarin (BMRN) to $100 from $80 and keeps a Buy rating on the shares. The company's proposed acquisition of Amicus (FOLD) hits all the right notes based on the following, including two approved rare disease drugs aligns with BioMarin's rare disease focus, the analyst tells investors in a research note. The deal is also accretive within 12 months post close in Q2 and substantially accretive starting 2027 given that Amicus is a profitable biotech, Truist notes, adding that the combination having twice the size of greater geographic reach of BioMarin vs. Amicus could drive continued growth into relatively long exclusivity into 2037.
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
